Trevena ( Trevena)

Primary tabs

Trevena's picture

Management

Contact Address

About Trevena

Trevena is a publicly traded clinical stage biopharmaceutical company based in King of Prussia, PA, dedicated to the discovery and development of GPCR biased ligands. Established in late 2007, Trevena was created to translate groundbreaking research on GPCR signaling into a new generation of medicines. We have three programs in clinical development: TRV027, currently in phase 2 clinical testing for the treatment of acute heart failure; TRV130, currently in phase 2 testing for the intravenous treatment of postoperative pain; and TRV734, currently in phase 1 testing for oral treatment of acute and chronic pain. In addition, Trevena has built an early-stage portfolio of drug discovery programs currently in lead optimization.

Trevena press release, blog etc

Wed, 07/10/2024 - 18:51 Trevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty Financing
Wed, 11/16/2022 - 10:24 Trevena, Inc. Announces $8.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Wed, 11/09/2022 - 16:26 Trevena Announces Reverse Stock Split
Fri, 07/29/2022 - 09:23 Trevena, Inc. Announces Registered Direct Offering of Preferred Stock
Thu, 07/28/2022 - 21:10 Trevena, Inc. Announces Closing of Registered Direct Offering of Preferred Stock
Mon, 06/13/2022 - 20:24 Trevena Announces the Publication of an Expert Review on the Clinical Profile of OLINVYK in Post-Operative Care
Mon, 04/18/2022 - 09:37 Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ex-US Royalty-Based Financing with R-Bridge Healthcare Fund
Tue, 04/12/2022 - 20:53 OLINVYK data selected as Presidents Choice abstract at Annual Regional Anesthesiology and Acute Pain Medicine Meeting and Featured at American Burn Association Annual Meeting
Thu, 03/31/2022 - 11:40 Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare Fund, an affiliate of CBC Group
Wed, 01/26/2022 - 21:53 Trevena Announces Submission of New Drug Application in China for OLINVYK by its Partner Jiangsu Nhwa Pharmaceutical
Mon, 01/03/2022 - 08:18 Trevena to Participate in the Upcoming January Conferences
Sun, 12/12/2021 - 21:40 Trevena Announces Advancement of TRV045 Into Clinical Development for Diabetic Neuropathic Pain
Wed, 10/13/2021 - 15:31 Trevena Announces Two OLINVYK Presentations at ANESTHESIOLOGY 2021
Thu, 09/16/2021 - 20:26 Trevena to Present at the Oppenheimer 2021 Fall Healthcare Life Sciences & MedTech Summit
Thu, 09/09/2021 - 01:39 Trevena to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Mon, 08/30/2021 - 17:00 Trevena Announces Two OLINVYK Abstracts Highlighting Safety Data Accepted at ANESTHESIOLOGY 2021
Tue, 08/24/2021 - 23:05 Trevena Announces Wake Forest Baptist Health Joining OLINVYK Clinical Outcomes Study
Mon, 08/09/2021 - 19:49 Trevena Announces Publication Highlighting Risk / Benefit Analysis of OLINVYK in Pain and Therapy
more

InfoBox

HomePagewww.trevenainc.com
LinkedInwww.linkedin.com/company/trevena-inc
Wikipediaen.wikipedia.org/wiki/Trevena_Inc